Intravenous Immunoglobulin Plus Interferon-α in Autoimmune Hepatitis C

BioDrugs

Volumn 18, Issue 1, 2004, Pages 63-70

  Malaguarnera, Mariano ^a   Guccione, Nicoletta ^a   Musumeci, Salvatore ^b   Brogna, Alfio ^a   Motta, Massimo ^a   Di Fazio, Ignazio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; SMOOTH MUSCLE ANTIBODY;

ADULT; ADVERSE DRUG REACTION; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFECT; DRUG HYPERSENSITIVITY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; IMMUNOLOGY; KIDNEY MICROSOME; LIVER MICROSOME; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIROLOGY; VOMITING;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; SEVERITY OF ILLNESS INDEX;

EID: 1242318735     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418010-00006     Document Type: Article

References (39)

1. Mans MP. Recent development in autoimmune liver disease. J Gastroenterol Hepatol 1997; 12: 256-71
2. Malaguarnera M, Restuccia N, Laurino A, et al. Maladies immunologiques et virus de l'hépatite C. Rev Med Interne 1996; 17: 305-12
3. Siciliano R, Trovato BA, Seminara G, et al. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Ann Ital Med Int 1995 Jul-Sep; 10 (3): 193-4
4. Malaguarnera M, Di Fazio I, Ferlito L, et al. A comparison of four types of interferon alpha in the treatment of chronic hepatitis C. Curr Ther Res 1998; 59: 48-59
5. Malaguarnera M, Di Fazio I, Restuccia S, et al. Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha. Ann Med 1998 Apr; 30 (2): 213-7
6. Zauli D, Cassani F, Bianchi FB. Auto-antibodies in hepatitis C. Biomed Pharmacother 1999 Jun; 53 (5-6): 234-41
7. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997 Feb; 26 (4): 689-701
8. Bayraktar Y, Bayraktar M, Gurakar A, et al. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases. Hepatogastroenterology 1997 Mar-Apr; 44 (14): 417-25
9. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997 Sep; 26 (3): 561-6
10. Wada M, Kang KB, Kinugasa A, et al. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 1997 (Apr); 36 (4): 248-54
11. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994 Nov; 94 (5): 1729-35
12. Dalakas MC. Illa I, Dambrosia JM. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993 Dec 30; 329 (7): 1993-2000
13. Tomer V, Shoenfeld V. Successful treatment of psychosis secondary to SLE, with high-dose intravenous immunoglobulin. Clin Exp Rheumatol 1992; 10: 391-3
14. Imbach P, Barandun S, d'Appuzo, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 Jun 6; I (8232): 1228-31
15. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome: Dutch Guillain-Barré Study Group. N Engl J Med 1992 Apr 23; 326 (17): 1123-9
16. Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996 Jan; 46 (1): 100-3
17. Van Doom PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990 Feb; 40 (2): 209-12
18. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994 Dec; 36 (6): 838-45
19. Vermeulen M, van Doom PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993 Jan; 56(1): 36-9
20. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Brain 1996 Aug; 119 (Pt 4): 1067-77
21. Dwyer JM. Manipulating the immune system with immunoglobulin. Clin Exp Immunol 1992; 97: 79-83
22. Ronda N, Hurez V, Kazatchkine MD. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 1993; 64 (2): 65-72
23. Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations: University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995 Jun 21; 273 (23): 1865-70
24. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993 Oct; 18 (4): 998-1005
25. Becker-Andre M, Hahlbrock K. Absolute mRNA quantification using the polymerase chain reaction (PCR): a novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Res 1989 Nov 25; 17 (22): 9437-46
26. Torp-Pedersen S, Vyberg M, Smith E, et al. Surecut 0.6 mm liver biopsy in the diagnosis of cirrhosis. Liver 1990 Aug; 10 (4): 217-20
27. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 Jun; 19 (6): 1513-20
28. Ishac K, Baptista A, Branchi I, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9
29. Scheuer PJ, Davies SE, Dhillon AP. Histopathological aspects of viral hepatitis. J Viral Hep 1996; 3: 277-83
30. Manns MP, Johnson EF, Griffin KJ, et al. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989 Mar; 83 (3): 1066-72
31. Antonelli G, Currenti M, Turriziani O, et al. Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-alpha preparations. J Infect Dis 1992 Mar; 165 (3): 593-4
32. Kawamoto H, Sakaguki K, Takaki A, et al. Autoimmune responses as assessed by ipergammaglobulinemia and the presence of autoantibodies in patients with chronic hepatitis C. Acta Med Okayama 1993; 47: 305-10
33. Malaguarnera M, Restuccia S, Trovato G, et al. Interferon alpha treatment in patients with chronic hepatitis C: a meta-analytic evaluation. Clin Drug Invest 1995; 9 (3): 141-9
34. Sherer Y, Levy Y, Fabrizzi F. Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today (Bare) 1999 Jul; 35 (7): 513-8
35. Lories RJ, Maertens JA, Ceuppens JL, et al. The use of polyclonal intravenous immunoglobulins in the prevention and treatment of infectious disease. Acta Clin Belg 2000 May-Jun; 55 (3): 163-9
36. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993 Mar; 341 (8848): 789-90
37. Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002 Jan; 35 (1): 224-31
38. McHutchison J, Patel K. Future therapy of hepatitis C. Hepatology 2002 Nov; 36 (5 Suppl. 1): S245-52
39. Malaguarnera M, Restuccia S, Motta M, et al. Interferon, cortisone, and antivirals in the treatment of chronic viral hepatitis: a review of 30 years of therapy. Pharmacotherapy 1997 Sep-Oct; 17 (5): 998-1005